TCI Biotech, a global contract development and manufacturing organization (CDMO) for nutraceuticals, functional foods, and skin care, announced a $26 million expansion to its existing manufacturing facility in American Fork, UT.

The expansion will upgrade capacity and strengthen the company’s operational footprint in North America, enhancing its localized manufacturing capabilities as part of its long-term commitment to the U.S. market. The company will progressively introduce selected production processes to its Utah facility, further advancing supply chain localization and operational efficiency.

TCI Biotech generates about 30% of its revenue from the U.S. market, and aims to make the U.S. one of its most important long-term growth sources. The expansion also underscores the company’s commitment to U.S. manufacturing, it reported.

The new site, which just launched a powder sachet production line, is expected to have liquid and jelly sachet production in the future. The company will also expand its clinical research and product development capabilities, creating new employment opportunities locally.

TCI Biotech has operations in the U.S., China, the Netherlands, Japan, Thailand, India, Vietnam, and Indonesia. Its global footprint enables access to high-growth markets, shortened supply chain cycles, worldwide collaboration, and reduced costs related to tariffs and logistics.

The present investment is part of the company’s efforts to offer one-stop solutions globally, including natural ingredients, research, product design, production, market promotion , and distribution, all in compliance with globally-recognized standards.